bioAffinity Technologies, Inc. filed a Form 8-K on October 29, 2026, disclosing that the company will participate in the Lung Cancer Initiative of North Carolina's Battle of the Blues event, joining physicians, patients, and other healthcare providers to highlight advancements in lung cancer diagnostics and therapies.

Key Highlights

  • Event participation: bioAffinity Technologies will join the Lung Cancer Initiative of North Carolina's Battle of the Blues event, according to the filing.
  • Attendees: The company will participate alongside physicians, patients, and other healthcare providers, as disclosed in the press release.
  • Focus area: The event will highlight advancements in new diagnostics and therapies improving the lives of patients with lung cancer, per the filing.
  • Press release date: The press release attached as Exhibit 99.1 was issued on October 29, 2026.
  • Emerging growth company: The registrant indicated it is an emerging growth company as defined under applicable SEC rules.

bioAffinity Technologies Announces Participation in North Carolina Lung Cancer Event

bioAffinity Technologies, Inc. (NASDAQ:BIAF), a Delaware corporation headquartered at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217, filed a current report disclosing its planned participation in the Lung Cancer Initiative of North Carolina's Battle of the Blues. According to the filing, the announcement was made via a press release issued on October 29, 2026, the same date as the earliest reported event.

The filing was made under Item 8.01, "Other Events," and states that the company "will join physicians, patients and other healthcare providers at the Lung Cancer Initiative of North Carolina's Battle of the Blues that will highlight advancements in new diagnostics and therapies that are improving the lives of patients with lung cancer." The press release, attached as Exhibit 99.1, is incorporated by reference into the filing.

The Form 8-K was signed by Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies, Inc. The company's common stock trades on the Nasdaq Capital Market under the symbol BIAF, and its warrants to purchase common stock trade under the symbol BIAFW, also on the Nasdaq Capital Market. The common stock carries a par value of $0.007 per share, as stated in the filing's registered-securities table.

What Was Disclosed

bioAffinity Technologies disclosed via an Item 8.01 current report that it will participate in the Lung Cancer Initiative of North Carolina's Battle of the Blues event, with a related press release attached as Exhibit 99.1 and dated October 29, 2026.